Surrozen reported $0 revenue and $129.72 million net loss for Q3 2026

Surrozen (SRZN) filed a 10-Q with the SEC on Nov 9, 2026, 4:59 pm ET. Source: the filing on SEC EDGAR.

Quarterly report, 7 new risk factors

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

What changed since last quarter

7 new risk factors · 5 removed · 2 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

New risk factors (7)

• failure of us or Boehringer Ingelheim to adequately perform under the CLA, including in connection with our ongoing arbitration, or the termination of the CLA;
In particular, the treatable population for our candidates may further be reduced if its estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from SZN-413, SZN-8141, or SZN-8143.
• Collaborators may interpret the terms of our agreements differently than we do, which could lead us to disagreements and disputes which could diminish the value of such collaboration to us. For example, in October 2026, Boehringer Ingelheim filed a request for arbitration with the ICC, asserting that we had…
"first-to-file" system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier.
In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which… +1 more paragraph
and 2 more in the filing

Removed risk factors (5)

• failure of us or Boehringer Ingelheim International GmbH to adequately perform under the Collaboration and License Agreement;
Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January 1, 2018 are permitted to be carried forward for only 20 taxable years under applicable U.S…
• Collaborators may interpret the terms of our agreements differently than we do, which could lead us to disagreements and disputes which could diminish the value of such collaboration to us. For example, Boehringer Ingelheim has recently advised us that it believes it has grounds to assert a contractual remedy under…
In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, was enacted, which… +2 more paragraphs
Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;

New legal mentions (2)

In October 2026, Boehringer Ingelheim filed a request for arbitration with the International Court of Arbitration of the International Chamber of Commerce, or the ICC, asserting that the Company had materially breached the CLA and seeking a 50% reduction of its royalty and milestone payment obligations and repayment… +2 more paragraphs
In October 2026, Boehringer Ingelheim filed a request for arbitration with the International Court of Arbitration of the International Chamber of Commerce, or the ICC, asserting that we had materially breached the CLA and seeking a 50% reduction of its royalty and milestone payment obligations and repayment of $5.0… +3 more paragraphs